Literature DB >> 12195128

Protective effects of the flavonoid quercetin in chronic nitric oxide deficient rats.

Juan Duarte1, Rosario Jiménez, Francisco O'Valle, Milagros Galisteo, Raquel Pérez-Palencia, Felix Vargas, Francisco Pérez-Vizcaíno, Antonio Zarzuelo, Juan Tamargo.   

Abstract

OBJECTIVES: The present study analysed, for the first time, the effects of the flavonoid quercetin in rats after chronic inhibition of nitric oxide (NO) synthesis with Nomega-nitro-L-arginine methyl ester (L-NAME).
DESIGN: Rats were divided randomly into five different treatment groups for 6 weeks: (1) vehicle (control, 1 ml of 1% methylcellulose once daily); (2) vehicle plus L-NAME (75 mg/100 ml in drinking water); (3) quercetin (10 mg/kg p.o. once daily); (4) quercetin (5 mg/kg p.o.) plus L-NAME; and (5) quercetin (10 mg/kg p.o.) plus L-NAME.
METHODS: The evolution of systolic blood pressure, morphological variables, proteinuria, plasma malondialdehyde and nitrite and nitrate concentrations, hepatic glutathione and malondialdehyde content, glutathione enzymes activity and vascular reactivity at the end of the experiment were analysed.
RESULTS: Quercetin markedly inhibited the development of L-NAME-induced hypertension. This effect was accompanied by a partial or full prevention of most of the effects induced by L-NAME, such as: (1) increases in the left ventricular and kidney weight indices; (2) proteinuria; (3) renal histological lesions, including hyaline arteriopathy and thickening of the vascular wall with moderate decrease of the lumen; (4) increased endothelium-dependent contraction; (5) increased vascular thromboxane B2 (TXB2) synthesis; (6) reduced plasma concentrations of nitrites plus nitrates (NOx); (7) increased plasma and hepatic malondialdehyde (MDA) concentrations; and (8) reduced glutathione peroxidase activity. In most cases these effects were dose dependent, but none of them were observed in normotensive animals.
CONCLUSIONS: This study confirms and extends the previous evidence about the antihypertensive effects and end-organ protection of the flavonoid quercetin in animal models of hypertension.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12195128     DOI: 10.1097/00004872-200209000-00031

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  26 in total

1.  Systemic antioxidant properties of L-carnitine in two different models of arterial hypertension.

Authors:  Alfonso Mate; José L Miguel-Carrasco; María T Monserrat; Carmen M Vázquez
Journal:  J Physiol Biochem       Date:  2010-05-27       Impact factor: 4.158

2.  Acute intake of quercetin from onion skin extract does not influence postprandial blood pressure and endothelial function in overweight-to-obese adults with hypertension: a randomized, double-blind, placebo-controlled, crossover trial.

Authors:  Verena Brüll; Constanze Burak; Birgit Stoffel-Wagner; Siegfried Wolffram; Georg Nickenig; Cornelius Müller; Peter Langguth; Birgit Alteheld; Rolf Fimmers; Peter Stehle; Sarah Egert
Journal:  Eur J Nutr       Date:  2016-02-29       Impact factor: 5.614

3.  Effects of chronic quercetin treatment in experimental renovascular hypertension.

Authors:  María Francisca García-Saura; Milagros Galisteo; Inmaculada Concepción Villar; Almudena Bermejo; Antonio Zarzuelo; Félix Vargas; Juan Duarte
Journal:  Mol Cell Biochem       Date:  2005-02       Impact factor: 3.396

4.  Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat.

Authors:  G Rossoni; B Manfredi; V De Gennaro Colonna; M Berti; M Guazzi; F Berti
Journal:  Br J Pharmacol       Date:  2007-01-22       Impact factor: 8.739

Review 5.  Therapeutic potential of quercetin to decrease blood pressure: review of efficacy and mechanisms.

Authors:  Abigail J Larson; J David Symons; Thunder Jalili
Journal:  Adv Nutr       Date:  2012-01-05       Impact factor: 8.701

6.  Quercetin restores plasma nitrite and nitroso species levels in renovascular hypertension.

Authors:  Marcelo F Montenegro; Evandro M Neto-Neves; Carlos A Dias-Junior; Carla S Ceron; Michele M Castro; Valeria A Gomes; Alexandre Kanashiro; Jose E Tanus-Santos
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-08-08       Impact factor: 3.000

7.  Antiasthmatic activity of quercetin glycosides in neonatal asthmatic rats.

Authors:  Suyue Zhu; Haijun Wang; Jun Zhang; Chunlin Yu; Chengquan Liu; Haiping Sun; Yunduo Wu; Yumei Wang; Xiaofei Lin
Journal:  3 Biotech       Date:  2019-04-26       Impact factor: 2.406

8.  The renoprotective effect of L-carnitine in hypertensive rats is mediated by modulation of oxidative stress-related gene expression.

Authors:  Sonia Zambrano; Antonio Jesús Blanca; María Victoria Ruiz-Armenta; José Luis Miguel-Carrasco; Elisa Revilla; Consuelo Santa-María; Alfonso Mate; Carmen María Vázquez
Journal:  Eur J Nutr       Date:  2012-12-06       Impact factor: 5.614

9.  Effects of chronic quercetin treatment on antioxidant defence system and oxidative status of deoxycorticosterone acetate-salt-hypertensive rats.

Authors:  Milagros Galisteo; Maria Francisca García-Saura; Rosario Jiménez; Inmaculada Concepción Villar; Antonio Zarzuelo; Félix Vargas; Juan Duarte
Journal:  Mol Cell Biochem       Date:  2004-04       Impact factor: 3.396

10.  Effects of Luteolin on Liver, Kidney and Brain in Pentylentetrazol-Induced Seizures: Involvement of Metalloproteinases and NOS Activities.

Authors:  Hüsniye Birman; Kadriye Akgün Dar; Ayşegül Kapucu; Samet Acar; Gülay Uzüm
Journal:  Balkan Med J       Date:  2012-06-01       Impact factor: 2.021

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.